The largest trial of ERAs, SONAR, including 2648 participants with type 2 diabetes and proteinuric CKD, demonstrated that atrasentan on top of RAS inhibition significantly lowered the risk of a doubling of serum creatinine or ESKD compared with placebo by 35% [75]
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
Promotion of fat loss : GLP-1 therapy specifically targets fat loss rather than muscle mass, which helps improve body composition during weight loss
GLP-/GIP dual agonist innovatively integrates the effects of two incretin into one molecule, which can simultaneously activate GLP-1R and GIPR
Weight Loss in Fernandina Beach, FL & Jacksonville, FL How does tirzepatide work
The once-weekly dosing and gradual dose escalation protocol may help minimise side effects